Trade Ocugen, Inc. - OCGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0131 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024901% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002679% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.9969 |
| Open | 0.9969 |
| 1-Year Change | 144.94% |
| Day's Range | 0.9877 - 1.0169 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Oct 4, 2024 | 0.9969 | 0.0399 | 4.17% | 0.9570 | 1.0169 | 0.9570 |
| Oct 3, 2024 | 0.9444 | -0.0032 | -0.34% | 0.9476 | 0.9693 | 0.9369 |
| Oct 2, 2024 | 0.9644 | 0.0275 | 2.94% | 0.9369 | 0.9887 | 0.9169 |
| Oct 1, 2024 | 0.9484 | -0.0405 | -4.10% | 0.9889 | 0.9929 | 0.9378 |
| Sep 30, 2024 | 0.9831 | -0.0138 | -1.38% | 0.9969 | 1.0169 | 0.9569 |
| Sep 27, 2024 | 1.0069 | 0.0200 | 2.03% | 0.9869 | 1.0369 | 0.9869 |
| Sep 26, 2024 | 0.9774 | -0.0495 | -4.82% | 1.0269 | 1.0269 | 0.9670 |
| Sep 25, 2024 | 1.0169 | 0.0300 | 3.04% | 0.9869 | 1.0469 | 0.9818 |
| Sep 24, 2024 | 0.9727 | -0.0442 | -4.35% | 1.0169 | 1.0269 | 0.9328 |
| Sep 23, 2024 | 1.0369 | -0.0700 | -6.32% | 1.1069 | 1.1069 | 1.0369 |
| Sep 20, 2024 | 1.1169 | -0.0200 | -1.76% | 1.1369 | 1.1369 | 1.0869 |
| Sep 19, 2024 | 1.1269 | 0.0000 | 0.00% | 1.1269 | 1.1569 | 1.1169 |
| Sep 18, 2024 | 1.1069 | -0.0100 | -0.90% | 1.1169 | 1.1669 | 1.0969 |
| Sep 17, 2024 | 1.1169 | -0.0800 | -6.68% | 1.1969 | 1.1969 | 1.0969 |
| Sep 16, 2024 | 1.1669 | -0.0400 | -3.31% | 1.2069 | 1.2269 | 1.1569 |
| Sep 13, 2024 | 1.1969 | 0.0000 | 0.00% | 1.1969 | 1.2169 | 1.1769 |
| Sep 12, 2024 | 1.1969 | -0.0200 | -1.64% | 1.2169 | 1.2269 | 1.1869 |
| Sep 11, 2024 | 1.2269 | 0.0100 | 0.82% | 1.2169 | 1.2569 | 1.2069 |
| Sep 10, 2024 | 1.2358 | 0.0400 | 3.35% | 1.1958 | 1.2358 | 1.1858 |
| Sep 9, 2024 | 1.2358 | 0.1000 | 8.80% | 1.1358 | 1.2358 | 1.1358 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ocugen, Inc. Company profile
Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine.
Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.
Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.
The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).
The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD).
Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.
Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.
Ocugen is headquartered in Malvern, Pennsylvania.
| Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
News
Gold's recent Story
Last week, we explored the key price drivers of gold, and how they impacted the price of the precious metal this year and last. Now, we’ll bring these factors to life in a chart, showing you ten instances the gold price responded to critical fundamental events, including central bank policies, global economic data, and geopolitical events.
15:36, 7 October 2024
September US Non-Farm Payrolls Preview
Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.
07:59, 2 October 2024
Market of the Month - Gold, an overview
In 2024, gold has been on an upward trajectory, hitting high after high as global markets face ongoing challenges. This precious metal, long seen as a safe haven, has been proving its worth, drawing attention from traders around the world as its bullish surge continues.
06:00, 30 September 2024
RBA Preview: Rates to remain unchanged with inflation-fighting still the focus
RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.
12:27, 20 September 2024
BoE Preview: no change expected but forward guidance will be key
The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.
14:53, 19 September 2024
FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion
Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.
11:30, 19 September 2024
Bank of Japan Preview
The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.
09:40, 17 September 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com